Home >> Tag Archives: BioTheranostics—

Tag Archives: BioTheranostics—

Biotheranostics, Syapse collaboration, 1/17

January 2017—Biotheranostics and Syapse plan to integrate data from Biotheranostics’ CancerType ID and Breast Cancer Index genomic tests into the Syapse Precision Medicine Platform. The software-based service is part of Syapse’s global partner program, which aims to leverage strong collaborators toward an integrative approach to precision medicine.

Read More »

Biotheranostics tests join Syapse platform

Oct. 17, 2016—Biotheranostics and Syapse announced they will integrate data from Biotheranostics’ CancerType ID and Breast Cancer Index genomic tests into the Syapse Precision Medicine Platform. The software-based service is part of Syapse’s global partner program that aims to leverage strong collaborators toward an integrative approach to precision medicine. The collaboration aims to allow for seamless integration of patient-specific results ...

Read More »

BioTheranostics leaves BioMerieux fold

Feb. 4, 2016—Molecular diagnostics company BioTheranostics announced has closed a $32 million financing led by MVM Life Science Partners, with participation of Canepa Advanced Healthcare Fund and HealthQuest Capital. As a result of the financing, BioTheranostics will be spun out from BioMerieux, which will remain a minority shareholder, and operate as an independent company. “This is an exciting new beginning ...

Read More »

BioTheranostics, DeNovo join for liquid biopsy work

Oct. 26, 2015—BioTheranostics announced a collaboration agreement with DeNovo Sciences, a player in the emerging liquid biopsy field, to investigate the technical feasibility of using BioTheranostics’ proprietary biomarkers in the development of blood-based diagnostics. These proof-of-concept studies will leverage proprietary platforms to enable molecular characterization with BioTheranostics biomarkers using circulating tumor cells enriched and captured with DeNovo’s microfluidic platform to ...

Read More »

Studies support role of BioTheranostics’ tests, 7/15

July 2015—BioTheranostics announced that clinical study data disclosed at the American Society of Clinical Oncology annual meeting in June demonstrate that its CancerType ID molecular cancer classifier and CancerTreatment NGS+ biomarker tests provide actionable genomic information to support an accurate diagnosis and treatment of metastatic cancers.

Read More »
X